Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Multifunctional Peptide Conjugate Meets Criteria in Joint Research: PeptiDream/Santen
January 26, 2023
- Ono/KSQ Therapeutics Tie Up for Cancer Drug Discovery
January 26, 2023
- Takeda Gets Rights to Hutchmed’s Colorectal Cancer Med Outside China
January 25, 2023
- Astellas to Divest Antifungal Micafungin to Sandoz for Up to US$75 Million Upfront
January 25, 2023
- Moderna, NCGM Ink MOU to Push mRNA-Based Healthcare
January 24, 2023
- J-Pharma’s Biliary Tract Cancer Med Hits Mark in Japan PII Study
January 24, 2023
- Alzheimer’s Drug Leqembi Now Available in US: Eisai/Biogen
January 24, 2023
- US FDA Lifts Clinical Hold of Astellas’ Pompe Gene Therapy
January 23, 2023
- Acoalan’s PIII Trial for Preeclampsia Due to Complete in July: Kyowa Kirin
January 23, 2023
- Meiji’s Stelara Biosimilar Shows Therapeutic Equivalence; Filing Eyed in 2023
January 23, 2023
- CSL Behring Launches App to Manage Hizentra Treatment Records
January 20, 2023
- Eisai Starts Stand-Alone Biz Operations in Israel
January 20, 2023
- Opdivo Outdistances Keytruda in 2022 with Sales Up 30 Billion Yen YOY: Encise
January 20, 2023
- Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
- Shionogi Commences New COVID Vaccine Trials for Children
January 18, 2023
- Chiome, China Firm Call off License Deal for Anti-TROP-2 Antibodies
January 18, 2023
- Chugai to End Sale of Joint Function Improving Agent Suvenyl in Japan
January 17, 2023
- Towa Set to Take on Legal Battle over Treakisym Patent
January 17, 2023
- Toray Rolls Out Remitch OD Tablets in South Korea
January 17, 2023
- Alzheimer’s Med Lecanemab Submitted in Japan: Eisai
January 16, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…